Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.46 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69747 | 0.89 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL29508473 | 0.89 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL29268187 | 0.86 | MAPK1 (0.74) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL989398 | 0.85 | MAPK1 (0.79) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL64700 | 0.85 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 | |
| SCHEMBL18104354 | 0.84 | MAPK1 (0.61) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL378814 | 0.84 | MAPK1 (0.77) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL5717551 | 0.84 | MAPK1 (0.77) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| Hydrochloric Acid SCHEMBL6553707 | 0.84 | MAPK1 (0.96) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 | |
| SCHEMBL600512 | 0.82 | MAPK1 (0.74) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| CN-116157398-B | Oxadiazole-based selective histone deacetylase 6 inhibitors | 意大发马克股份公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4457224-A1 | HETEROCYCLIC COMPOUNDS | BeiGene Switzerland GmbH (CH) | 2024-11-06 | — | — | EP | disclosed |
| US-20240327417-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-03 | — | — | US | disclosed |
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN BIOTECH, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2024160276-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| CN-118451073-A | Heterocyclic compounds | 百济神州有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-117881661-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-0678087-B1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARM INC (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5780676-A | BICYCLIC BENZYL, PYRIDINYL, THIOPHENE, FURANYL, PYRROLE, AND POLYENOIC ACID DERIVATIVES | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0678087-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678086-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0637297-A4 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS. | LIGAND PHARM INC (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995004036-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994015902-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994015901-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327417-A1 | HETEROCYCLIC COMPOUNDS | NFATC1, CD4, ACIN1 | MAPK1 983/4885KDM4E 2752/4885L3MBTL1 4624/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | MAPK1 392/4885KDM4E 2066/4885L3MBTL1 4317/4885 |
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | MAPK1 4056/4885KDM4E 3515/4885L3MBTL1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.